Free beta access. 5 free AI tokens each week. Optional top-ups available. See what is included
Opening Word document…

Restrictions on germline genetic editing would crush business confidence – venture capitalist are hugely invested.

Brian Gormley, 3-10-2022, Brian Gormley is a Special Writer covering life sciences for Dow Jones VentureWire. He joined Dow Jones in 2004."Venture Investment in Crispr Gene Editing Spurs Innovation, Hunt for IP," WSJ, https://www.wsj.com/articles/venture-investment-in-crispr-gene-editing-spurs-innovation-hunt-for-ip-11646910000

Increasing venture-capital investment in gene-editing technology is fueling a rush to secure intellectual property in a sector that promises to spur advances across several areas of biotechnology.Technology known as Crispr enables researchers to make precise changes, or edits, to the genetic code, which could lead to therapies for genetic diseases, cancer and other conditions. Because of its broad commercial potential, the gene-editing technology has been surrounded by intellectual-property disputes for several years.In one such dispute, U.S. patent authorities ruled that the Broad Institute, a partnership including the Massachusetts Institute of Technology and Harvard University, was first to invent a method of editing plant and animal cells using the enzyme Cas9, a type of molecular scissors that can cut DNA.The dispute pitted Broad against the University of California, Berkeley, the University of Vienna and Emmanuelle Charpentier, who shared the 2020 Nobel Prize in Chemistry with Berkeley professor Jennifer Doudna for their Crispr-Cas9 research.The U.S. Patent and Trademark Office decision affects companies that use Cas9, favoring those with ties to the Broad, including Editas Medicine Inc., and going against drugmakers such as Intellia Therapeutics Inc. that have licenses from the University of California and its partners.Intellia last week said it had filed patent applications for its own Crispr-Cas9 innovations and that it doesn't expect the ruling to affect its ability to develop future Crispr-based medicines.Several Crispr-based startups raising venture capital recently are using enzymes other than Cas9 to enable new applications for gene editing, avoid existing patents, and generate new intellectual property. Last week's ruling will spur even more Crispr innovation, said Katherine Ann Rubino, chair of the life-sciences practice group for law firm Caldwell Intellectual Property Law.Globally, venture capitalists invested $1.08 billion in 31 Crispr startup financings last year, compared with $172.9 million in 18 such deals in 2020, according to market tracker PitchBook Data Inc. Part of the appeal is the efficiency, specificity and simplicity of Crispr gene editing, said Ursheet Parikh, a partner with venture firm Mayfield. 

Sign in to recut, update, or save this card.